Topic Primary open-angle glaucoma (POAG) is a highly prevalent condition worldwide and
the most common cause of irreversible sight loss. The objective is to assess the comparative …

Introduction: Several large, randomized, prospective clinical trials have demonstrated that
medical therapy to reduce intraocular pressure (IOP) delays the onset and decreases …

Background: Network meta-analysis compares multiple treatment options for the same
condition and may be useful for developing clinical practice guidelines. Purpose: To …

ABSTRACT Introduction Fixed dose combinations (FCs) represent a potentially valuable
treatment strategy in glaucoma management. Fixed combinations not only improve …

Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other
intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but …

Objective: To investigate the effects of two different medical treatment options on choroidal
thickness (CT) in cases of open-angle glaucoma (OAG). Methods: Sixty-seven eyes newly …

Glaucoma is the leading cause of irreversible blindness and the aim of all glaucoma
treatments is to lower intraocular pressure (IOP), the only modifiable risk factor. This article …

Background. The aim of this study was to compare the daily costs and cost effectiveness of
fixed combination glaucoma drugs in China. Methods. This study included the following …

Purpose To evaluate the safety and efficacy of adding fixed-combination brinzolamide
1%/brimonidine 0.2%(BBFC) as adjunctive therapy to travoprost 0.004%(TRAV) in patients …

Glaucoma is one of the leading causes of blindness and is characterized by optic nerve
damage that results in visual field loss. Elevated intraocular pressure (IOP) has been …